In contrast, ELR-negative chemokines such as CXCL9, CXCL10, and CXCL11 are classically viewed as anti-tumor agents due to their angiostatic and immune modulatory effects mediated by their shared receptor, CXCR3 [39,50]. This evidence concerns the gene CXCL9 and neoplasm.